Evidence Mapping of Proton Therapy, Heavy Ion Therapy, and Helical Tomotherapy for Gastric Cancer

Li, Muyang; Dou, Wenshan; Lin, Yingfeng; Li, Qianqian; Xu, Huimei; Zhang, Dekui

doi:10.1159/000518997

Cited by 3 publications

(3 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Evidence mapping in oncology has also seen an expansion beyond cancer treatments [39][40][41][42][43][44][45][46][47][48] to include molecular pathogenesis, 49 risk factors, 50,51 complications 52 and nutritional intervention. 53 Nicholson et al 54 proposed the usage of citation index and tools that incorporate artificial intelligence in helping researchers to find relevant scientific literature, as searching for the most highly cited papers in an area of interest is one of the possible approaches for sifting and dealing with massive numbers of publications.…”

Section: Discussionmentioning

confidence: 99%

Mapping the cited evidence of ductal carcinoma in situ from the 5th edition of the World Health Organisation classification of tumours of the breast

Wong,

Md Nasir,

Koh

et al. 2024

Histopathology

View full text Add to dashboard Cite

AimsDuctal carcinoma in situ (DCIS) is recognised by the World Health Organisation (WHO) Classification of Tumours (WCT) as a non‐invasive neoplastic epithelial proliferation confined to the mammary ducts and lobules. This report categorises the references cited in the DCIS chapter of the 5th edition of the WCT (Breast Tumours) according to prevailing evidence levels for evidence‐based medicine and the Hierarchy of Evidence for Tumour Pathology (HETP), identifying potential gaps that can inform subsequent editions of the WCT for this tumour.Methods and resultsWe included all citations from the DCIS chapter of the WCT (Breast Tumours, 5th edition). Each citation was appraised according to its study design and evidence level. We developed our map of cited evidence, which is a graphical matrix of tumour type (column) and tumour descriptors (rows). Spheres were used to represent the evidence, with size and colour corresponding to their number and evidence level respectively. Thirty‐six publications were retrieved. The cited literature in the DCIS chapter comprised mainly case series and were regarded as low‐level. We found an unequal distribution of citations among tumour descriptors. ‘Pathogenesis’ and ‘prognosis and prediction’ contained the most references, while ‘clinical features’, ‘aetiology’ and ‘diagnostic molecular pathology’ had only a single citation each. ‘Prognosis and prediction’ had the greatest proportion of moderate‐ and high‐levels of evidence.ConclusionOur findings align with the disposition for observational studies inherent in the field of pathology. Our map is a springboard for future efforts in mapping all available evidence on DCIS, potentially augmenting the editorial process and future editions of WCTs.

show abstract

Section: Discussionmentioning

confidence: 99%

Mapping the cited evidence of ductal carcinoma in situ from the 5th edition of the World Health Organisation classification of tumours of the breast

Wong,

Md Nasir,

Koh

et al. 2024

Histopathology

View full text Add to dashboard Cite

show abstract

“…Efforts to include evidence mapping for cancer have so far covered therapeutic interventions, clinical management, alternative treatments, and adjunctive testing. [55][56][57][58][59][60][61][62][63] A limitation of this report is the possibility of unintended citation selection bias. As the chapter authors were invited to contribute to the Blue Book based on their publication record, there might understandably be an inclination to include publications that they had participated in, reflecting their subject expertise and publication content familiarity.…”

Section: Discussionmentioning

confidence: 99%

“…of studies which applied this method showed 39 publications from 2003 to 2015, but none surfaced for pathology. Efforts to include evidence mapping for cancer have so far covered therapeutic interventions, clinical management, alternative treatments, and adjunctive testing 55–63 …”

Section: Discussionmentioning

confidence: 99%

Phyllodes tumour evidence gaps mapped from the 5th edition of the WHO classification of tumours of the breast

et al. 2023

View full text Add to dashboard Cite

Phyllodes tumour evidence gaps mapped from the 5th edition of the WHO classification of tumours of the breast Aims: Breast phyllodes tumours (PTs) are a rare subset of fibroepithelial neoplasms categorised into benign, borderline, and malignant grades according to the World Health Organization (WHO) Classification of Tumours (WCTs). In this report, we developed an evidence gap map (EGM) based on the literature cited in the PT chapter of the 5th edition of the breast WCT in order to identify knowledge and research gaps in PT. Methods: A framework was first established where the dimensions of the EGM were defined as categories of tumour descriptors, tumour types, and evidence levels. Citations were collected into a Microsoft Excel form and imported into EPPI-reviewer to produce the EGM. Results: The EGM showed that the "Histopathology" and "Pathogenesis" sections contained the most citations, the majority being of low-level evidence. The highest number of citations considered of moderatelevel evidence were found in the "Histopathology" section. There was no high-level evidence cited in this chapter. The "Localisation", "Aetiology", and "Staging" sections had the fewest citations. Conclusion:This EGM provides a visual representation of the cited literature in the PT chapter of the breast WCT, revealing the lack of high-level evidence citations. There is an uneven distribution of references, probably due to citation practices. Pockets of low-level evidence are highlighted, possibly related to referencing habits, lack of relevant research, or the belief that the information presented is standard accepted fact, without the need for specific citations. Future work needs to bridge evidence gaps and broaden citations beyond those in the latest WCT.

show abstract

Dosimetric comparison of 3D-Conformal and IMRT techniques used in radiotherapy of gastric cancer: A retrospective study

Gul,

Demir,

Kanyilmaz

et al. 2024

IJCESEN

View full text Add to dashboard Cite

This study aimed to compare three-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT) planning techniques commonly used in gastric cancer radiotherapy with dose volume histograms. Computed tomography (CT) images of 20 gastric cancer patients were retrospectively analyzed. 3D-CRT, 5F- IMRT and 7F- IMRT treatment plans were created for each patient. The 3 plans were compared on dose volume histogram (DVH). 3D-CRT, 5F-IMRT and 7F-IMRT plans achieved a prescribed dose of 45 Gy for 95% of PTV volume. D95 values were 45.06±0.47 Gy for 3DCRT, 46.39±0.38 Gy for 5F-IMRT and 45.20±0.11 Gy for 7F-IMRT. In 3D-CRT, 5F-IMRT and 7F-IMRT techniques, the 13 Gy receiving volumes of the right kidney were found to be 35.08+9.59, 36.25+7.97 and 37.03+9.03 respectively. Moreover, the volume of the right kidney receiving a 20 Gy and 30 Gy dose received less dose with 5F-IMRT than with 7F-IMRT. Since each patient's critical organs are at different distances from the target and each technique has its own advantages in terms of critical organs, we suggest that the useful technique should be decided by clinical consensus.

show abstract

Evidence Mapping of Proton Therapy, Heavy Ion Therapy, and Helical Tomotherapy for Gastric Cancer

Cited by 3 publications

References 41 publications

Mapping the cited evidence of ductal carcinoma in situ from the 5th edition of the World Health Organisation classification of tumours of the breast

Mapping the cited evidence of ductal carcinoma in situ from the 5th edition of the World Health Organisation classification of tumours of the breast

Phyllodes tumour evidence gaps mapped from the 5th edition of the WHO classification of tumours of the breast

Dosimetric comparison of 3D-Conformal and IMRT techniques used in radiotherapy of gastric cancer: A retrospective study

Contact Info

Product

Resources

About